Semler Scientific ( (SMLR) ) has released its Q3 earnings. Here is a breakdown of the information Semler Scientific presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Semler Scientific, Inc. is a healthcare technology company specializing in diagnostic and testing solutions, primarily serving the medical device industry with its flagship product, QuantaFlo, used for detecting peripheral arterial disease.
In its latest earnings report for the quarter ending September 30, 2025, Semler Scientific reported a significant decrease in revenues compared to the previous year, alongside a notable net income driven by changes in fair value of digital assets and other income sources. The company continues to navigate challenges in its core business operations while exploring new strategic directions.
Key financial highlights include a decrease in quarterly revenues to $7.5 million from $13.5 million in the same period last year, attributed to reduced testing volumes and changes in the Medicare reimbursement landscape. Despite the revenue drop, Semler reported a net income of $16.9 million, largely due to a $28.5 million gain from the change in fair value of its digital assets, specifically Bitcoin, which the company holds as part of its investment strategy.
The company faces ongoing challenges, including regulatory hurdles and customer attrition, but remains focused on expanding its product offerings and exploring strategic mergers, such as the proposed business combination with Strive, Inc. Looking ahead, Semler’s management is cautiously optimistic, emphasizing the potential for growth through strategic initiatives and continued investment in digital assets, while acknowledging the volatility and risks associated with these ventures.